NCT04587479View on ClinicalTrials.gov

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2023

Conditions
Solid Tumors, Adult
Interventions
DRUG

JAB-8263

Variable dose, orally Q2D with 28 days each cycle

Trial Locations (3)

32025

RECRUITING

Florida Cancer Center, Lake Mary, Lake City

37203

RECRUITING

Tennessee Oncology Nashville, Nashville

80218

RECRUITING

SCRI HeatlthONE, Denver

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY